Crossmark

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

Crossref DOI link: https://doi.org/10.1038/s41571-019-0216-2

Published Online: 2019-05-03

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

D’Abreo, Nina

Adams, Sylvia
License Information

Text and Data Mining valid from 2019-05-03
More Information

Article History

First Online: 3 May 2019

Competing interests

: S.A. declares that she has received research funding to her institution from Merck, Genentech, Amgen, Celgene, Bristol-Myers Squibb (BMS) and Novartis and that she is a Steering committee member for IMpassion130 (uncompensated), a Global PI on Keynote-086 (uncompensated) and a consultant for BMS (uncompensated). N.D’A. declares no competing interests.